Goldman Ends Endo Coverage Following Q2 EBITDA Guide
NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide
One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.
